CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 156 filers reported holding CLOVIS ONCOLOGY INC in Q1 2015. The put-call ratio across all filers is 1.84 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $166 | -61.8% | 139,904 | -42.1% | 0.00% | – |
Q2 2022 | $435 | -99.9% | 241,621 | -18.7% | 0.00% | – |
Q1 2022 | $600,000 | -55.2% | 297,021 | -39.9% | 0.00% | – |
Q4 2021 | $1,340,000 | -40.4% | 494,457 | -1.8% | 0.00% | – |
Q3 2021 | $2,247,000 | +7.3% | 503,752 | +39.5% | 0.00% | – |
Q2 2021 | $2,094,000 | -61.9% | 361,026 | -53.9% | 0.00% | -100.0% |
Q1 2021 | $5,498,000 | +67.4% | 783,149 | +14.5% | 0.00% | 0.0% |
Q4 2020 | $3,284,000 | +87.2% | 684,199 | +127.4% | 0.00% | – |
Q3 2020 | $1,754,000 | +53.7% | 300,872 | +78.0% | 0.00% | – |
Q2 2020 | $1,141,000 | -90.4% | 168,984 | -91.0% | 0.00% | -100.0% |
Q1 2020 | $11,917,000 | +45.8% | 1,873,793 | +139.1% | 0.00% | +100.0% |
Q4 2019 | $8,171,000 | +218.9% | 783,702 | +20.2% | 0.00% | +100.0% |
Q3 2019 | $2,562,000 | -68.9% | 651,778 | +17.7% | 0.00% | -50.0% |
Q2 2019 | $8,234,000 | -53.2% | 553,740 | -21.9% | 0.00% | -60.0% |
Q1 2019 | $17,597,000 | +189.9% | 708,970 | +109.8% | 0.01% | +400.0% |
Q4 2018 | $6,069,000 | -41.7% | 337,937 | -4.6% | 0.00% | -66.7% |
Q3 2018 | $10,404,000 | -43.8% | 354,234 | -13.0% | 0.00% | -40.0% |
Q2 2018 | $18,523,000 | -13.4% | 407,364 | +0.5% | 0.01% | 0.0% |
Q1 2018 | $21,397,000 | -15.8% | 405,241 | +8.4% | 0.01% | -16.7% |
Q4 2017 | $25,421,000 | -21.8% | 373,838 | -5.2% | 0.01% | -25.0% |
Q3 2017 | $32,505,000 | -27.2% | 394,486 | -17.3% | 0.01% | -27.3% |
Q2 2017 | $44,678,000 | +13.0% | 477,164 | -23.1% | 0.01% | 0.0% |
Q1 2017 | $39,527,000 | +9.6% | 620,815 | -23.5% | 0.01% | 0.0% |
Q4 2016 | $36,059,000 | -5.0% | 811,767 | -22.9% | 0.01% | -8.3% |
Q3 2016 | $37,940,000 | +45.9% | 1,052,420 | -44.5% | 0.01% | +33.3% |
Q2 2016 | $26,013,000 | +16.1% | 1,896,027 | +62.5% | 0.01% | +28.6% |
Q1 2016 | $22,401,000 | -69.2% | 1,166,729 | -43.8% | 0.01% | -69.6% |
Q4 2015 | $72,679,000 | +826.2% | 2,076,532 | +2333.5% | 0.02% | +666.7% |
Q3 2015 | $7,847,000 | -27.4% | 85,330 | -30.6% | 0.00% | 0.0% |
Q2 2015 | $10,810,000 | +12.5% | 123,009 | -5.0% | 0.00% | 0.0% |
Q1 2015 | $9,609,000 | -50.1% | 129,447 | -62.3% | 0.00% | -50.0% |
Q4 2014 | $19,249,000 | +12.0% | 343,740 | -9.3% | 0.01% | 0.0% |
Q3 2014 | $17,184,000 | +3.9% | 378,836 | -5.2% | 0.01% | +20.0% |
Q2 2014 | $16,543,000 | -1.5% | 399,500 | +64.7% | 0.01% | 0.0% |
Q1 2014 | $16,799,000 | +72.3% | 242,518 | +49.9% | 0.01% | +66.7% |
Q4 2013 | $9,752,000 | -7.3% | 161,798 | -6.5% | 0.00% | -25.0% |
Q3 2013 | $10,516,000 | +285.6% | 172,961 | +324.8% | 0.00% | +300.0% |
Q2 2013 | $2,727,000 | – | 40,716 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |